Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab - Merck & Co

X
Drug Profile

Pembrolizumab - Merck & Co

Alternative Names: KEYTRUDA; Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 16 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune-Onc Therapeutics; Merck & Co; The Leukemia & Lymphoma Society
  • Developer Aduro BioTech; AIO Studien gGmbH; ALX Oncology; Amgen; ARCAGY/GINECO Group; Astellas Pharma; Atara Biotherapeutics; Augusta University; Bayer; BerGenBio; Big Ten Cancer Research Consortium; BioLineRx; BioNTech; Canadian Cancer Trials Group; Celgene Corporation; Celyad Oncology; Centre Leon Berard; Columbia University; Curie Institute; Dana-Farber Cancer Institute; DNAtrix; Duke University; Eisai Co Ltd; Eli Lilly and Company; European Network of Gynaecological Oncological Trial Groups; Fox Chase Cancer Center; Fusion Pharmaceuticals; Genexine; Genome & Company; Gilead Sciences; H. Lee Moffitt Cancer Center and Research Institute; Highlight Therapeutics; Hoosier Cancer Research Network; Icahn School of Medicine at Mount Sinai; ImmunoGen; Incyte Corporation; IngenOx Therapeutics; Institut fuer Frauengesundheit; Institute of Cancer Research; IO Biotech; Ipsen; M. D. Anderson Cancer Center; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; Merck & Co; Merck Sharp & Dohme; Moderna Therapeutics; National Cancer Institute (France); National Cancer Institute (USA); Netherlands Cancer Institute; Netris Pharma; North Eastern German Society of Gynaecological Oncology; Northwestern University; Novartis; NYU Langone Medical Center; Oslo University Hospital; Presage Biosciences; Providence Health & Services; Royal Marsden NHS Foundation Trust; Samsung Medical Center; Sarcoma Alliance for Research through Collaboration; Seagen; Sellas Life Sciences Group; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Breast Cancer Research Group; Stanford University; Syndax Pharmaceuticals; TG Therapeutics Inc; University College London; University Health Network; University of Alabama; University of Birmingham; University of California at San Francisco; University of California, San Diego; University of Colorado at Denver; University of Miami; University of Pittsburgh; University of Ulm; University of Utah; University of Washington; Verastem Oncology; Wakayama Medical University; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Oesophageal cancer; Merkel cell carcinoma; Malignant melanoma; Follicular lymphoma; Liver cancer; Gastric cancer; Diffuse large B cell lymphoma; Hodgkin's disease; Nasopharyngeal cancer; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Biliary cancer; Breast cancer; Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Registered Bladder cancer; Cancer; Merkel cell carcinoma
  • Preregistration Malignant-mesothelioma
  • Phase III Fallopian tube cancer; Gastrointestinal cancer; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer
  • Phase II Acute myeloid leukaemia; Adenoid cystic carcinoma; Bone cancer; Brain metastases; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Ewing's sarcoma; Follicular lymphoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioblastoma; Glioma; Inflammatory breast cancer; Kaposi's sarcoma; Leucoplakia; Liver metastases; Lymphoma; Malignant fibrous histiocytoma; Malignant thymoma; Marginal zone B-cell lymphoma; Meningeal carcinomatosis; Meningioma; Myelodysplastic syndromes; Neuroendocrine tumours; Neurofibrosarcoma; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Rectal cancer; Recurrent respiratory papillomatosis; Richter's syndrome; Sarcoma; Skin cancer; Soft tissue sarcoma; Thyroid cancer; Uveal melanoma
  • Phase I/II Haematological malignancies; Leiomyosarcoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Phase I Cutaneous T-cell lymphoma; Gliosarcoma
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 16 Jun 2024 3858135: Added clinical data in KDM, sci section and HE
  • 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
  • 29 May 2024 Preregistration for Malignant mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top